Chem. Pharm. Bull. 18(4) 784-788 (1970)

UDC 547.964.4.04.07

Peptides. II. A New Synthetic Method for the Amino-protected Amino Acid Activated Esters^{1,2)}

MASUMI ITOH

Research Laboratories, Fujisawa Pharmaceutical Co., Ltd.3)

(Received December 8, 1969)

A facile procedure for the preparation of amino-protected amino acid activated ester was studied.

Dimethylaryloxyformimidium chloride (V), which was easily prepared from aryl chloroformate (II) and dimethylformamide under the evolution of carbon dioxide, was allowed to react with amino-protected amino acids to give the corresponding activated aryl esters.

Activated ester method is a one of very important procedures for the stepwise elongation of sequential peptides⁴⁾ so that a large number of investigations on the new activated esters has been reported.^{4–11)} Of these esters, some aryl esters such as p-nitrophenyl, trichlorophenyl and pentachlorophenyl esters are frequently utilized for practical peptide synthesis. For the preparation of these activated esters several procedures are known^{4,5)} and some improved procedures, for example, transesterification method using trifluoroacetate,^{12,13)} dichloroacetate or trichloroacetate,¹⁴⁾ or decomposition of mixed anhydride prepared from N-benzyloxycar-bonylamino acids with succinimidoxycarbonyl chloride¹⁵⁾ have also been proposed.

On the other hand, Vilsmeier–Haack reagents, dimethyl chloroformimidium chloride and related reagents, were utilized as coupling agent in peptide synthesis. ^{16–19}) Furthermore, the reaction of methanol with dimethylaryloxyformimidium chlorides prepared from aryl chloroformates with dimethylformamide (DMF) were demonstrated recently their effectiveness for the protection and regeneration of phenolic hydroxyl group. ²⁰) However, these use for ester synthesis has not been reported.

In the present paper a new facile procedure for the synthesis of amino-protected amino acid aryl esters using dimethylaryloxyformimidium chlorides are described. On mixing DMF

¹⁾ Part I.M. Itoh, Chem. Pharm. Bull. (Tokyo), 17, 1679 (1969). Most part of this work was presented at the 7th Symposium on Peptide Chemistry, Tokyo Univ., Nov. 21—22, 1969.

²⁾ Abbreviation used for protecting groups, amino acids and peptides are those recommended by IUPAC-IUB commission on biochemical nomenclature: *Biochemistry*, 5, 2485 (1966).

³⁾ Location: 1, Kashima-cho, Higashiyodogawa-ku, Osaka.

⁴⁾ E. Schröder and K. Lübke, "The Peptides," Vol. I, Academic Press Inc., New York, 1966, pp. 97-108.

⁵⁾ M. Bodanszky and M. Ondetti, "Peptide Synthesis," Interscience Publishers, 1966, pp. 98-109.

⁶⁾ G.W. Anderson, "Annual Reports in Medicinal Chemistry," edited by C.K. Cain, 1965, pp. 289-290.

⁷⁾ E. Taschner, B. Rzeszotarska and L. Lubiewska, Chem. Ind. (London), 1967, 402.

⁸⁾ K. Lloyd and G.T. Young, Chem. Commun., 1968, 1400.

⁹⁾ Yu. V. Mitin and L.B. Nadezhdina, J. Gen. Chem., USSR (English Transl.), 38, 2542 (1968).

¹⁰⁾ B.J. Johnson and P.M. Jacobs, J. Org. Chem., 33, 4524 (1968).

¹¹⁾ J.H. Jones and G.T. Young, J. Chem. Soc. (C), 1968, 436.

¹²⁾ S. Sakakibara and N. Inukai, Bull. Chem. Soc. Japan., 38, 1979 (1965).

¹³⁾ B. Rzeszotarska and G.P. Vlasov, Bull. Acad. Polon. Sci. Ser. Sci. Chim., 15, 143 (1967).

¹⁴⁾ M. Fujino and C. Hatanaka, Chem. Pharm. Bull. (Tokyo), 16, 929 (1968).

¹⁵⁾ H. Gross and L. Bilk. Ann., 725, 212 (1969).

¹⁶⁾ M. Zaoral and Z. Arnold, Tetrahedron Letters, 1960, 9.

¹⁷⁾ L. Novak and J. Weichet, Experientia, 21, 360 (1965).

¹⁸⁾ G.W. Kenner and R.J. Stedman, J. Chem. Soc., 1952, 2069.

¹⁹⁾ F. Cramer and M. Winter, Chem. Ber., 94, 989 (1961).

²⁰⁾ V.A. Pattison, J.G. Colson and R.L.K. Carr, J. Org. Chem., 33, 1084 (1968).

with a solution of pentachlorophenyl chloroformate in inert solvent a vigorous reaction takes place under evolution of carbon dioxide gas. When the same reaction was carried out on cooling, the precipitate was first formed and then carbon dioxide gas evolved gradually on warming to room temperature. The structure of precipitated hygroscopic salt was confirmed to be dimethylpentachlorophenoxyformimidium chloride (Vc) by the following data; infrared (IR) (Nujol, cm⁻¹): $1660 (C=N^+)$, and 1280 (aryl ether); nuclear magnetic resonance (NMR) $(\delta(ppm), in CD_3OD)$: two set of signals owing to tautomers appeared at $2.95 (singlet, =N-CH_3)$, $3.08 (singlet, =N-CH_3)$ and 8.10 (singlet, -CH-), and at $3.26 (singlet, =N-CH_3)$, 3.44 (singlet, -CH-) and 8.75 (singlet, -CH-).

The reaction mechanism may be presented as in Chart 1.20) Other immonium salts (Va—Vg) were also prepared from chloroformates and secondary amides, however, the formation of

Chart I

those immonium salts were limited to aryl chloroformates or succinimidoxycarbonyl chloride because the reaction of alkyl chloroformates with DMF afforded only alkyl chlorides.²²⁾ The reaction of those immonium salts with various acids was recognized to proceed smoothly in the presence of tertiary amine at room temperature and completed generally within 20 minutes to give activated esters. If the reaction is carried out in the absence of tertiary amine, it needs more longer reaction time and the yield is rather low.

This procedure has some advantages if the considerabler stable chloroformates is available: procedure is rather simple and suitable for large scale preparation, a short reaction time is required and formed components is very easily removable. Esters thus prepared are listed in the Table I. Direct coupling of formed activiated ester with amino acid and peptide esters are also examined (Table II).

²¹⁾ NMR spectrum was measured with a Varian A-60 spectrometer using tetramethylsilane as an internal standard. DMF (in CD₃OD; δ (ppm)) shows signals at 2.86 (singlet, 3H), 3.00 (singlet, 3H) and 7.97 (singlet, 1H), so that immonium salt Vc may not be decomposed in CD₃OD.

²²⁾ H. Eilingsfeld, M. Seefelder and H. Weidinger, Angew. Chem., 72, 836 (1960).

TABLE I.	Activated Esters of Amino-protected Amino
	Acidsa) and Salicylic Acid

	Immonium salt	Base	\mathbf{Yield} (%)	mp (°C) Found/Lit.	$[\alpha]_{D}^{t}$ (c, solvent) Found/Lit.
Z-Asp(OBzl)-ONF	. Va	Et ₃ N	79	75 — 77	+12.0 ²³ (4, CHCl ₃)
				75 — 76	$+12.5^{30}$ (4, CHCl ₃) ²³⁾
Z-CyS(Bzl)-ONP	Va	$DMA^{b)}$	74	92.5— 93.5	-42.4^{26} (2, DMF)
				93 - 94	-43^{20} (2, DMF) ²⁴⁾
Z-CyS(Bzl)-OPCF	Vc	$DMA^{b)}$	77	168 —169	-34.0^{26} (0.7, CHCl ₃)
		,		171 —173	-34.3^{24} (0.7, CHCl ₃) ²⁵
Z-Gln-ONPc)	Va	$\mathrm{Et_{3}N}$	47	155 —157	-24.2^{23} (2, DMF)
				155 - 156	$-24^{20} (2, DMF)^{24}$
Z-Gly-OTCP	Vb	$\mathrm{Et_{3}N}$	70	100 —101	
				$102 - 104^{26}$	
Z-Gly-OPCP	Vc	$\mathrm{Et_{3}N}$	79	128 —130	
7 01 0T1		***		$133 - 134^{12}$	
Z-Gly-SPh	Ve	$\mathrm{Et_{3}N}$	55	72 - 73.5	
7 DI 077	***	T3. 37	0.4	$70 - 72^{26}$	FO 092 (4 TOME)
Z-Phe-OHsu	Vd	$\mathrm{Et_{3}N}$	81	136 —138.5	-53.2^{23} (1, DMF)
7 DI OTOD	T 71	TO AT	75	134 —136	-53.8^{24} (1, DMF) ¹²⁾
Z-Phe-OTCP	Vb	$\mathrm{Et_{3}N}$	75	140 —141	$-40.1^{23}(1, DMF)$
7 DL ODCD	37-	T24 NT	75	140 —141	$-39.4^{24}(1, DMF)^{26}$
Z-Phe-OPCP	Vc V~	$\mathrm{Et_{3}N}$	75 55	154 - 155 $154 - 156$	-49.5^{25} (1, DMF)
	Vg	•••••	ออ	159 —160	-49.4^{24} (1, DMF) ²⁶⁾
Z-Pro-ONP	Va	$\mathrm{Et_{3}N}$	82	94 - 96	-49.4^{-1} (1, DMF) -68.2^{25} (2, DMF)
Z-F10-ONF	v a	الاوات	04	94 - 96 $94 - 96$	-68^{20} (2, DMF) ²⁴⁾
Z-Tyr(Bzl)-ONP	Va	$\mathrm{Et_{3}N}$	76	147 — 148	$-8.6^{23}(2, DMF)$
	٧a	271321	70	148 —150	-9^{20} (2, DMF) ²⁴⁾
Z-Val-ONP	Va	$\mathrm{Et_{3}N}$	60	62 - 64	$-9^{\circ}(2, DMF)$ $-25.0^{23}(2, DMF)$
D- var-OIVI	٧ ۵		O O	63	-24.4^{20} (2, DMF) ²⁷⁾
o-HO-C ₆ H ₄ -ONP	Va	Pv^{d}	54	143 —145°)	
J 220 06214 0111	, u	- 3	0.1	$151.5 - 151.9^{28}$	

a) Used amino acids are all L-configuration except glycine.

Table II. Preparation of Acylated Peptide Esters via Activated Estersa)

	Immonium salt	Base	Yield (%)	mp (°C) Found/Lit.	$[\alpha]_D^f$ (c, solvent) Found/Lit.
Z-Leu-Gly-OEt	Va	Et ₃ N	71	102 —104 102.5—103.5	-27.4 ²² (5, EtOH) -27.5 ²⁰ (5, EtOH) ²⁹⁾
Z-Trp-Gly-OBzl	Va	DMAb)	67	122 —124 117 —118	-21.1^{23} (0.95, MeOH) -19 ± 1^{25} (0.95, MeOH) ³⁰⁾
Z-Pro-Leu-Gly-OEt	Va	$\mathrm{Et_{3}N}$	67	150 —152 151 —152	-81.2 ²⁴ (2.5, EtOH) -82.6 ²³ (2.5, EtOH) ²⁴⁾

a) Used amino acids are all L-configuration except glycine.

b) DMA=dimethylaniline

c) DMF was used as solvent. d) Py=pyridine

e) Anal. Calcd. for C₁₃H₉O₅N: C, 60.23; H, 3.50; N, 5.40. Found: C, 60.58; H, 3.25; N, 4.99

b) DMA=dimethylaniline

²³⁾ L. Zervas and C. Hamalidis, J. Am. Chem. Soc., 87, 99 (1965).

²⁴⁾ M. Bodanszky and V. du Vigneaud, J. Am. Chem. Soc., 81, 5688 (1959).

²⁵⁾ J. Kovacs, M.Q. Ceprini, C.A. Dupraz and G.N. Schmit, J. Org. Chem., 32, 3696 (1967).

²⁶⁾ Y. Wolman, D. Ladkany and M. Frankel, J. Chem. Soc. (C), 1967, 689.

²⁷⁾ B. Iselin, W. Rittel, P. Sieber and R. Schwyzer, Helv. Chim. Acta., 40, 373 (1957).

²⁸⁾ N.G. Gaylord and P.M. Kamath, Org. Synth., 32, 25 (1952).

²⁹⁾ S. Sakakibara and M. Itoh, Bull. Chem. Soc. Japan., 40, 656 (1967).

³⁰⁾ H. Kappeler, Helv. Chim. Acta., 44, 476 (1961).

Unfortunately, this procedure is not suitable for the preparation of peptidic activated esters, because Anderson's racemization test³¹⁾ shows complete racemization even if mild bases^{29,32)} is utilized at lower temperature. The mechanism for ester formation may be presented as in Chart 2.

$$\begin{bmatrix} R_1 & R_3 \\ R_2 & N = C - X - Ar \end{bmatrix} Cl^{-1} \xrightarrow{CONH - CHCOO^{-1}} \begin{bmatrix} R_1 & R_3 \\ R_2 & N - C - X - Ar \\ 0 & 0 = C - Ar \\ 0 & 0 = C - Ar \end{bmatrix} \xrightarrow{R_5} - CHNH - C - VII$$

$$V = \begin{bmatrix} R_1 & R_3 & R_5 \\ 0 & N - C - X - Ar \\ 0 & 0 = C - Ar \\ 0 & N - - Ar$$

Chart 2

When the amino-protecting group is urethane type which has not been observed oxazolone formation, nucleophilic attack of carboxyl carbon atom by the $Ar-X^-$ anion preferentially affords the optically activated esters. On the contrary, when amino-protected peptides is used, the reaction proceeds through the oxazolone intermediate (VIII) to give racemized product.

Experimental

All melting points are uncorrected and taken on a Hoover "Uni-Melt" apparatus. Optical rotations were measured with a Yanagimoto photo-magnetic polarimerter, Model OR-10. Reaction mixture was examined by thin-layer chromatography on silica gel G in chloroform-acetic acid-methanol (95:3:5). Spots were demonstrated by the combination of hydrogen bromide and ninhydrin for N-benzyloxycarbonyl derivatives.

Materials——p-Nitrophenyl chloroformate,³³⁾ 2,4,5-trichlorophenyl chloroformate,³⁴⁾ pentachlorophenyl chloroformate³⁵⁾ and succinimidoxycarbonyl chloride¹⁵⁾ were prepared according to the literature.

Dimethylpentachlorophenoxyformimidium Chloride (Vc)—Dry DMF (3 ml) was added all at once into a well stirred solution of pentachlorophenyl chloroformate (4.0 g, 0.012 mole) in dry tetrahydrofuran (20 ml; dry benzene, toluene, DMF etc is also suitable as solvent) on ice-cooling. White precipitate appeared soon and then carbon dioxide gas evolved gradually on warming to room temperature. The suspension was used directly for ester formation without further treatment. For analysis filtered precipitate was washed with dry tetrahydrofuran, dried over phosphorous pentoxide and measured its IR and NMR spectra.

Other immonium salts, dimethyl-p-nitrophenoxyformimidium chloride (Va), dimethyl-2,4,5-trichlro-rophenoxyformimidium chloride (Vb), dimethylsuccinimidoxyformimidium chloride (Vd), dimethylphenyl-thioformimidium chloride (Ve), dimethyl-p-nitrophenoxyacetoimidium chloride (Vf) and dimethylpentachloro-phenoxyacetoimidium chloride (Vg) were also prepared in a similar manner as described above for Vc. These immonium salts are unstable toward moisture.

General Procedure for the Preparation of Activated Esters—To the suspension of immonium salt (0.01-0.012 mole) prepared as described above a solution of N-benzyloxycarbonylamino acid (0.01 mole) and tertiary amine (0.01-0.012 mole) in suitable solvent (10-20 ml); chloroform, tetrahydrofuran, ethyl acetate or DMF etc) was added dropwise at room temperature. The reaction was completed generally within 10-20

³¹⁾ a) G.W. Anderson and F.M. Callahan, J. Am. Chem. Soc., 80, 2902 (1958); b) G.W. Anderson and R. Paul. J. Am. Chem. Soc., 82, 4596 (1960).

³²⁾ G.W. Anderson, J.E. Zimmerman and F.M. Callahan, J. Am. Chem. Soc., 88, 1338 (1966).

³³⁾ a) G.W. Anderson and A.C. McGregor, J. Am. Chem. Soc., 79, 6180 (1957); b) K. Inouye, M. Kanayama and H. Otsuka, J. Chem. Soc. Japan, 85, 599 (1964).

³⁴⁾ W. Broadbent, J.S. Morley and B.E. Stone, J. Chem. Soc. (C), 1967, 2632.

³⁵⁾ a) M. Fujino and C. Hatanaka, Chem. Pharm. Bull. (Tokyo), 15, 2015 (1967); b) M. Itoh and D. Morino, Experientia, 24, 101 (1968).

Vol. 18 (1970)

minutes. The formed ester was taken up to ethyl acetate and the extract was washed with water and dried over MgSO₄. The crude product was treated as described in the literature (see Table I).

General Procedure for the Direct Coupling of Activated Ester with Amine Component—N-Benzyloxy-carbonylamino acid p-nitrophenyl ester taken up to ethyl acetate as described above was coupled directly with amine component. A typical example is as follows: To a suspension of Va prepared from p-nitrophenyl chloroformate (1.2 g) with DMF (1.0 ml) in dry benzene (10 ml) a solution of N-benzyloxycarbonyltryptophan (1.6 g) and dimethylaniline (0.73 g) in dry tetrahydrofuran (10 ml) was added dropwise with stirring below 10°, and stirred further 2 hr at room temperature. The product was extracted with ethyl acetate and the extract was washed with water, dried over MgSO₄ and concentrated to about 20 ml. A solution of glycine benzyl ester p-toluenesulfonate (1.6 g) and triethylamine (0.7 ml) in chloroform (15 ml) was added to the above mentioned solution and the mixture was treated as described in the literature (see Table II).

Acknowledgement The author express his deep gratitude to Dr. S. Sakakibara of Institute for Protein Research Osaka Univercity, and Dr. H. Nakano, director of this laboratory for their kind advices and encouragements. Thanks are also to Mr. D. Morino for his skillful technical assistance.